EU Aproves Diabetes Drug
Find a Conversation
| Tue, 02-26-2008 - 4:02pm |
http://www.medscape.com/viewarticle/570612
EU Approves Novartis's Eucreas Diabetes Drug
ZURICH (Reuters) Feb 25 - The European Union approved Novartis's Eucreas oral treatment for diabetes, the Swiss drugmaker said on Monday, following its approval of Galvus (vildagliptin), one of the two-in-one drug's ingredients.
Eucreas combines vildagliptin, a DPP-4 inhibitor, and metformin.
"The approval comes after Novartis proposed changes to the EU label recommending that liver monitoring should be conducted," Novartis said in a statement.
The European Medicines Agency said in September it had backed Eucreas to treat type-2 diabetes. The Agency's recommendations are normally followed by approval in the 27-nation bloc.
The EU approved Galvus on Feb. 1 after Novartis said the label for the drug should warn for liver problems.






